Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Invested Capital (2016 - 2025)

Historic Invested Capital for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $622.4 million.

  • Amicus Therapeutics' Invested Capital rose 951.75% to $622.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.4 million, marking a year-over-year increase of 951.75%. This contributed to the annual value of $584.2 million for FY2024, which is 659.16% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Invested Capital of $622.4 million as of Q3 2025, which was up 951.75% from $595.6 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Invested Capital registered a high of $765.3 million during Q3 2021, and its lowest value of $495.2 million during Q1 2023.
  • Its 5-year average for Invested Capital is $579.4 million, with a median of $568.3 million in 2024.
  • As far as peak fluctuations go, Amicus Therapeutics' Invested Capital surged by 1878.13% in 2021, and later tumbled by 3154.96% in 2022.
  • Amicus Therapeutics' Invested Capital (Quarter) stood at $696.7 million in 2021, then fell by 26.08% to $515.0 million in 2022, then increased by 6.41% to $548.0 million in 2023, then increased by 6.59% to $584.2 million in 2024, then grew by 6.55% to $622.4 million in 2025.
  • Its Invested Capital stands at $622.4 million for Q3 2025, versus $595.6 million for Q2 2025 and $584.3 million for Q1 2025.